JP2022509568A5 - - Google Patents

Info

Publication number
JP2022509568A5
JP2022509568A5 JP2021552785A JP2021552785A JP2022509568A5 JP 2022509568 A5 JP2022509568 A5 JP 2022509568A5 JP 2021552785 A JP2021552785 A JP 2021552785A JP 2021552785 A JP2021552785 A JP 2021552785A JP 2022509568 A5 JP2022509568 A5 JP 2022509568A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
gip
peptide analog
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552785A
Other languages
English (en)
Japanese (ja)
Other versions
JP7605747B2 (ja
JP2022509568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Publication of JP2022509568A publication Critical patent/JP2022509568A/ja
Publication of JP2022509568A5 publication Critical patent/JP2022509568A5/ja
Application granted granted Critical
Publication of JP7605747B2 publication Critical patent/JP7605747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552785A 2018-12-03 2019-12-03 修飾されたgipペプチド類似体 Active JP7605747B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18209896.2 2018-12-03
EP18209896 2018-12-03
EP19176739 2019-05-27
EP19176739.1 2019-05-27
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues

Publications (3)

Publication Number Publication Date
JP2022509568A JP2022509568A (ja) 2022-01-20
JP2022509568A5 true JP2022509568A5 (enExample) 2022-12-07
JP7605747B2 JP7605747B2 (ja) 2024-12-24

Family

ID=68731999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552785A Active JP7605747B2 (ja) 2018-12-03 2019-12-03 修飾されたgipペプチド類似体

Country Status (12)

Country Link
US (3) US12187773B2 (enExample)
EP (2) EP3891173A1 (enExample)
JP (1) JP7605747B2 (enExample)
KR (2) KR20260011770A (enExample)
CN (3) CN121449721A (enExample)
AU (2) AU2019391300B2 (enExample)
BR (1) BR112021010447A2 (enExample)
CA (1) CA3121043A1 (enExample)
IL (1) IL283385A (enExample)
MX (1) MX2021006505A (enExample)
SG (1) SG11202105586YA (enExample)
WO (2) WO2020115048A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250346647A2 (en) * 2019-12-03 2025-11-13 Antag Therapeutics Aps Optimized GIP Peptide Analogues
CN116133677B (zh) * 2020-07-06 2026-04-17 鸿绪生物医药科技(北京)有限公司 新型多肽制剂及其治疗用途
US20230263896A1 (en) * 2020-07-06 2023-08-24 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic use thereof
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CA3221661A1 (en) * 2021-06-10 2022-12-15 Alexander HOVARD SPARRE-ULRICH Treatment of obesity and obesity-related disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
CN116120425A (zh) * 2022-12-27 2023-05-16 南京赛诺生物技术有限公司 一种glp-1/gip受体双重激动剂及其应用
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
CN121464151A (zh) * 2023-02-24 2026-02-03 Ip2Ipo创新有限公司 化合物
EP4687947A1 (en) * 2023-04-05 2026-02-11 Antag Therapeutics ApS Gip activity modulators and orthostatic intolerance
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5745335A (en) 1996-06-27 1998-04-28 Gennum Corporation Multi-layer film capacitor structures and method
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
ATE197408T1 (de) 1998-01-30 2000-11-11 Novo Nordisk As Eine injektionsspritze
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
EP1119625B1 (en) 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
US6921748B1 (en) 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2003028298A2 (en) 2001-09-21 2003-04-03 Koninklijke Philips Electronics N.V. No specific control module? use less specific one
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 gip 유사체 및 하이브리드폴리펩타이드
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
KR20110043687A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체
WO2010016940A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
ES2574835T3 (es) 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
US20190352335A1 (en) * 2016-12-19 2019-11-21 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
CN110099694A (zh) 2016-12-26 2019-08-06 花王株式会社 低体温改善剂
WO2018124010A1 (ja) 2016-12-26 2018-07-05 花王株式会社 認知機能改善剤
JP7165495B2 (ja) 2016-12-26 2022-11-04 花王株式会社 運動調節機能向上剤
KR102743887B1 (ko) * 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체

Similar Documents

Publication Publication Date Title
JP2022509568A5 (enExample)
JP7658877B2 (ja) インクレチン類似体およびその使用
JP7605747B2 (ja) 修飾されたgipペプチド類似体
JP5524049B2 (ja) 目的ペプチドの血漿中半減期延長作用を有するペプチド
JP2023505441A5 (enExample)
JP5635529B2 (ja) グルカゴン類似体
TWI670281B (zh) Gip-glp-1雙重促效劑化合物及方法
JP5635532B2 (ja) グルカゴン類似体
JP5969461B2 (ja) Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
JP2025172864A5 (enExample)
JP2012506402A5 (enExample)
JP2020521784A5 (enExample)
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
JP2012532898A (ja) アシル化グルカゴン類似体
JP2013523618A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2013505221A (ja) 長時間作用性y2受容体アゴニスト
JP2010538049A5 (enExample)
KR20110040760A (ko) 대사 질환 및 비만 치료용 gip-기초된 혼합형 항진제
CA2812951A1 (en) Engineered polypeptides having enhanced duration of action
JP2014527975A5 (enExample)
JP2013543497A5 (enExample)
JP2021535119A5 (enExample)
JP2013510829A (ja) 長時間作用型y2受容体アゴニスト